In a phase 4 trial, dupilumab effectively reduces airway inflammation and mucus plugging, improving lung function and asthma control in patients with moderate to severe type 2 asthma.

Dupilumab added to standard COPD triple therapy reduces the annual rate of moderate exacerbations but not severe exacerbations.

Dupilumab significantly reduced airway inflammation in patients with uncontrolled, moderate-to-severe type 2 asthma. Read now.

Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

1 Dupilumab is being jointly developed by Regeneron and Sanofi ... or inhaled corticosteroid medicines; have asthma and use an asthma medicine; or have atopic dermatitis, chronic rhinosinusitis with ...

n=3), asthma (n=4 vs. n=1), conjunctivitis (n=4 vs ... score Total cumulative OCS dose Time to first use of rescue medication Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits ...

Introduction Despite advancements in asthma management, many patients continue to experience poor disease control, lung function decline, and frequent exacerbations. Clinical remission (CR) has been ...

Lebrikizumab improves itch, sleep interference, and skin pain in atopic dermatitis patients previously treated with dupilumab, offering a new treatment option. A new Phase-3b study has found that ...

The American College of Allergy, Asthma and Immunology (ACAAI) is a professional medical organization headquartered in Arlington Heights, Illinois, U.S.A., that promotes excellence in the practice ...